Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEmvision Medical Devices Ltd

Emvision Medical Devices Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
1.44 AUD -0.02 ( 1.37%)
Last update at 2026-11-06T05:10:00Z
VOLUME
49913
Market Cap
133.86M

Momentum Score

…

EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia. It offers non invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients. The company was incorporated in 2017 and is based in Macquarie Park, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.39
Low
1.47
High
52 Week Price Range
1.42
Low
1.96
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Emvision Medical Devices Ltd is an Australian medical-technology company developing microwave-based brain imaging intended to support rapid stroke triage and intracranial haemorrhage detection in pre-hospital and acute-care settings. Long-term growth may be supported by successful clinical validation, regulatory clearance, hospital adoption and commercial partnerships, and the technology exposure to a large stroke-management market could be attractive to investors.

Key risks include execution and clinical risk as an early-stage, pre-commercial device developer with limited revenue, ongoing need for funding, regulatory and reimbursement uncertainty, and potential competition affecting adoption.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.46
Dividend Yield
-
Revenue TTM
8.36M
Revenue Per Share
0.09
Gross Profit TTM
8.36M
Debt / Equity
0.22
ROE
-66.39%
Net Debt
-13.70M
ROCE
-88.56%
Diluted EPS TTM
-0.09

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -13.29M -8.36M -2.03M -3.87M -6.11M
Net income -8.32M -9.81M -2.73M -3.87M -6.13M
Selling general administrative - 1.80M 1.83M 8.17M 7.42M
Selling and marketing expenses - 7.34M 6.31M - -
Gross profit -0.42M 5.05M 11.22M - -
Reconciled depreciation - 0.41M 0.41M 0.34M 0.24M
Ebit -16.93M -8.84M -8.76M -3.84M -6.09M
Ebitda -16.51M -8.71M -8.35M -3.49M -5.85M
Depreciation and amortization 0.42M 0.13M 0.41M 0.34M 0.24M
Operating income -16.93M -8.13M -1.61M -3.84M -6.09M
Other operating expenses 16.93M 13.18M 12.83M 10.93M 10.47M
Interest expense 0.20M 0.09M 0.12M 0.04M 0.02M
Tax provision - 1.45M 0.70M 0.00M 0.00M
Interest income - 0.58M 0.34M 0.04M 0.02M
Net interest income - 0.49M 0.23M 0.08M -0.00M
Income tax expense -4.97M 1.45M 0.70M 7.01M 0.02M
Total revenue - 5.05M 11.22M 4.59M 2.39M
Total operating expenses 16.51M 13.18M 12.83M 10.93M 10.47M
Cost of revenue 0.42M - 0.41M - -
Total other income expense net 3.64M -0.23M -0.42M 6.97M -0.02M
Net income from continuing ops - -9.81M -2.73M -3.87M -6.11M
Net income applicable to common shares - -9.81M -2.73M -3.87M -6.11M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 23.04M 15.57M 23.97M 11.52M 8.51M
Intangible assets 0.56M 0.61M - 0.48M 0.48M
Other current assets 0.23M 3.19M 0.35M 0.27M 0.07M
Total liab 7.27M 6.29M 5.46M 6.40M 1.43M
Total stockholder equity 15.77M 9.28M 18.52M 5.12M 7.08M
Other current liab 1.92M 0.87M 1.01M 2.30M 0.68M
Common stock 53.65M - 41.57M 26.23M 23.21M
Capital stock - 41.75M - 26.23M 23.21M
Retained earnings -41.17M -34.82M -26.52M -25.66M -21.79M
Other liab - - - 0.05M 0.03M
Cash 17.10M 10.46M 18.60M 9.97M 6.80M
Total current liabilities 3.92M 2.84M 3.41M 6.04M 0.85M
Current deferred revenue 0.81M - 1.05M 0.68M -0.20M
Net debt -13.70M - -15.70M -6.93M -6.06M
Short term debt 0.27M - 1.07M 2.73M 0.20M
Short long term debt - - - 2.50M -
Short long term debt total 3.41M - 2.90M 3.04M 0.74M
Other stockholder equity - - - 4.55M 5.66M
Property plant equipment - - - 0.80M 0.96M
Total current assets 21.70M 13.94M 21.87M 10.23M 7.07M
Net tangible assets - - - 4.64M 6.60M
Short term investments - 0.07M - 0.31M 0.18M
Net receivables 4.36M - 2.92M - 0.07M
Long term debt - 2.65M - - -
Accounts payable 0.92M 0.96M 0.29M 0.33M 0.18M
Accumulated other comprehensive income 3.28M - 3.46M 4.55M 5.66M
Non currrent assets other - -0.00M 0.65M -1.28M -1.44M
Non current assets total 1.34M 1.63M 2.10M 1.28M 1.44M
Capital lease obligations - 0.88M - 0.54M 0.74M
Long term debt total - - - 0.31M 0.54M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.05M -0.30M -0.19M -0.19M
Change to liabilities - - - 2.36M 0.04M
Total cashflows from investing activities -0.12M -0.05M -0.30M -0.19M -0.19M
Net borrowings - - - 2.53M -0.18M
Total cash from financing activities 13.02M -0.26M 15.00M 2.52M 1.08M
Change to operating activities - - - -0.00M 0.11M
Net income -8.32M -9.81M -2.73M -3.87M -6.11M
Change in cash 6.65M -8.14M 8.71M 3.17M -2.89M
Begin period cash flow 10.46M 18.60M 9.89M 6.80M 9.69M
End period cash flow 17.10M 10.46M 18.60M 9.97M 6.80M
Total cash from operating activities -6.25M -7.84M -5.99M 0.83M -3.78M
Issuance of capital stock - -0.00M 15.25M -0.01M 1.26M
Depreciation 0.42M - 0.41M 0.34M 0.24M
Other cashflows from investing activities - - -0.19M - -
Change to account receivables -1.16M -0.27M -0.14M 0.07M 0.05M
Sale purchase of stock - -0.00M 15.25M -0.01M 1.26M
Other cashflows from financing activities -0.14M 0.00M -0.24M 2.75M -0.19M
Change to netincome - - - 1.93M 1.89M
Capital expenditures 0.12M 0.05M 0.30M 0.19M 0.19M
Change in working capital -0.08M 0.91M -4.65M 0.07M 0.05M
Stock based compensation - - 0.87M 1.91M 1.88M
Other non cash items 1.73M -8.75M 1.39M 4.36M 2.09M
Free cash flow -6.37M -7.89M -6.29M 0.65M -3.97M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
EMV
Emvision Medical Devices Ltd		 -0.02
1.37%		 1.44 - - 16.02 8.61 -21.53
COH
Cochlear Ltd		 1.03
0.67%		 155.47 68.64 27.40 4.30 5.34 28.09
IMR
Imricor Medical Systems Inc		 -0.03
2.29%		 1.28 - - 36401.21 17.45 -2.60
AVR
Anteris Technologies Global Corp		 -0.36
4.21%		 8.20 - - 356.02 2.19 -5.20
AVH
Avita Medical Inc		 -0.08
1.73%		 4.55 - 9.97 9.59 7.17 15.37

Profile*

Emvision Medical Devices Ltd

EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia. It offers non invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients. The company was incorporated in 2017 and is based in Macquarie Park, Australia.

65 Epping Road, Macquarie Park, NSW, Australia, 2113

61 2 8667 5337

https://www.emvision.com.au

Name Title Year Born
Dr. Ronald Peter Weinberger AIMM, BSc (Hons), Ph.D. CEO, MD & Director NA
Mr. Scott Kirkland Exec. Director NA
Ms. Emma Waldon CFO & Company Sec. 1976
Dr. Konstanty Bialkowski Head of Technology Devel. NA
Prof. Stuart Crozier B.E., M.Sc., Ph.D. Chairman of Clinical Advisory Board & Chief Scientific Officer NA
Mr. Robert Tiller Head of Design NA
Ms. Forough Khandan Head of New Product Devel. NA
Dr. Merricc Edgar-Hughes Ph.D. Head of Quality & Regulatory Affairs NA
Dr. Konstanty Bialkowski Head of Tech Development NA
Mr. Scott Kirkland CEO, MD & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…